On April 9, 2020 Tango Therapeutics, a biotechnology company focused on discovering and delivering the next generation of targeted cancer therapies, reported the closing of an oversubscribed Series B financing of $60 million led by Boxer Capital of the Tavistock Group (Press release, Tango Therapeutics, APR 9, 2020, View Source [SID1234556226]). Cormorant Asset Management and Casdin Capital are additional new investors in the round.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are very fortunate to have the support of this strong syndicate of cross-over investors as we bring our first targeted therapies based on the genetic concept of synthetic lethality to well-defined patient populations," said Barbara Weber, MD, President and Chief Executive Officer of Tango. "This financing will support our lead program into IND-enabling studies early next year as well multiple other ongoing target and drug discovery efforts."
Additionally, Tango announced leadership appointments of Daniella Beckman, Chief Financial Officer, John C. Ross, Vice President of Human Resources and Samy Tadros, Vice President of Business Development.
Daniella Beckman, CPA, brings more than 20 years of strategic, financial and operational experience to her role at Tango overseeing finance, investor relations and business development. She served as interim Chief Financial Officer for Tango since its inception, and prior to that, for other early-stage biotechnology companies, including Neon Therapeutics. Previously, Ms. Beckman was the Chief Financial Officer of Idenix Pharmaceuticals, where she oversaw finance, investor relations and IT until it was acquired by Merck in 2014. Prior to serving as CFO, Ms. Beckman served as corporate controller for Idenix. She previously held finance positions at Coley Pharmaceuticals, Biogen Idec and PricewaterhouseCoopers. Ms. Beckman serves on the board of directors of Translate Bio. Ms. Beckman has a BA in business administration/accounting from Boston University and is a certified public accountant in Massachusetts.
John C. Ross, MS, MHRIR, joins Tango after serving as senior director of human resources for the surgical medical device business at Alcon, formerly a division of Novartis. Mr. Ross helped to facilitate the company’s spinoff from Novartis in 2019. Prior to Alcon, he served in multiple human resources leadership roles in Novartis Oncology and Novartis General Medicines in the U.S. and Europe. Mr. Ross also has held HR leadership roles at Google and Honeywell. Mr. Ross earned a BS in communications from the University of Texas at Austin and an MS in human resources and industrial relations from the University of Illinois.
Samy Tadros, MS, MBA, joins Tango from Celgene, recently acquired by Bristol Myers Squibb, where he served as Executive Director, Business Development and Global Alliances. Mr. Tadros spent more than ten years at Celgene, leading multiple cross-functional teams and closing many important transactions for Celgene. Mr. Tadros’ transactions spanned the spectrum from early research agreements to late stage development and commercialization deals. Before joining Celgene, Mr. Tadros worked at Charles River Labs and Schering-Plough. Mr. Tadros has a BS in biochemistry from Concordia University, an MS from the Temple University School of Pharmacy and an MBA from Fairleigh Dickinson University.
"We’re thrilled Daniella has agreed to join our team as CFO and to welcome John and Samy into these key leadership roles," added Dr. Weber. "Insights from all three industry leaders will be invaluable as we advance our pipeline of next-generation targeted cancer therapies and bring novel therapies to patients."